Onco Actu du 28 février 2018

	1. Biologie
GA4GH Releases 2018 Strategic Roadmap [Bio-IT World] The GA4GH 2018 Strategic Roadmap includes the first 28 standards and frameworks to be developed under GA4GH Connect, the organization’s five-year strategic plan focused on aligning with the key needs of the international genomic data community.
Q&A: Elaine Mardis and Rick Wilson on the First Cancer Genome and the Dawn of Clinical Genomics [Genome Web] All of the work really drives home the importance of patients who are willing to sign research consents to have their tumor material banked, because we would be nowhere if it were not for patients who have this altruistic idea that even though they probably won't be cured of their cancer, by donating it for research, they could help future patients.
	3.1 Prévention - Tabac
Why We Need Tailored Tobacco-control Strategies [Cancer Research Catalyst] Despite the progress, this means that there are still 36.5 million U.S. adults who are cigarette smokers.
	4.12 Biopsies liquides
Microfluidic device captures, allows analysis of tumor-specific extracellular vesicles [Mass. General Hospital] Specifically, we are interested in exploring how these vesicles change over time in response to treatment, and we see our blood-based assay as an ideal way to explore this in brain tumor patients.
	4.7 Dép., diag. & prono. - Col de l'utérus
Treatment or surveillance for CIN2: when less is more [BMJ] In young women in particular, expectant management is a valid option, as, in this group, up to 60% of CIN2 lesions regress under active surveillance within two years, and progression is extremely rare. This does not mean, however, that all women should be “left untreated”.
Thousands of women could be saved from invasive cervical cancer operations, research suggests [The Telegraph] The findings should help women make more informed choices with their doctor, but study limitations mean that the results should be interpreted with caution.
Some smear test abnormalities 'self-heal' [BBC News] The British Medical Journal research looked at the outcomes of more than 3,000 women and found half of the "moderate" lesions found on routine smear tests regressed spontaneously. The study authors stress it is still very important that women attend for cervical screening when invited.
	5.10 Traitements - Essais
Why is this trial due to report? [University of Oxford] In this blog post we are going to go through a single trial’s registry data, to ascertain whether it is required to report results, and if so, when.
	5.12.3 Immunothérapies-combinaisons
Bavarian Nordic’s cancer vaccine CV301 paired with Imfinzi, its third PD-1/L1 combo [FiercePharma] Following through on its strategy of showing CV301 could work in multiple tumor types, Bavarian Nordic has agreed to test the cancer vaccine in combination with AstraZeneca’s Imfinzi plus chemo in patients with metastatic colorectal or pancreatic cancers.
	5.12.5 Immunothérapies - Pharma
New York City-based immunotherapy startup Quentis comes to life with $48M [FierceBiotech] “We haven’t specifically decided which specific tumor types will be part of clinical development,” Aberman said. “We will disclose that as we get closer to a phase 1 study. There are a number to choose from that are correlated with elevated ER stress.”
Dana-Farber’s Laurie Glimcher helps launch a NYC biotech upstart with some key insights on immuno-oncology tech [EndPoints] That paper published in Cell in 2015, she said, “turned the field on its head.”
Quentis Nets $48M For Cancer Drugs, Building Buzz For NY Bio Startups [Xconomy] New York has nowhere near the number of high-profile biotech startups that Boston and San Francisco regularly churn out.
Quentis Therapeutics Debuts with $48 Million Series A Financing to Advance First-in-Class Immunotherapies Targeting Endoplasmic Reticulum Stress Response Pathways [Quentis] Quentis is pioneering first-in-class cancer immunotherapies that modulate endoplasmic reticulum (ER) stress response pathways in the tumor microenvironment. The Series A proceeds will support the advancement of Quentis’ lead program, a small molecule IRE1α inhibitor, into the clinic in 2019 and through clinical proof-of-concept.
New York Firm Raises $48 Million To Develop New Cancer Immunotherapies [Forbes] By turning down the body's stress response, which alters a network of tubes and membranes known as the endoplasmic reticulum, the immune system could have a better chance at fighting cancer and existing immune-boosting cancer drugs might have a better chance of proving effective.
	5.2.3 Pharma - économie
Where’s All That Money Going? (Pharma Edition) [In the Pipeline] Will we see more spending on research, though? More investment in smaller startups? Or will everyone just quietly buy back shares and bank their executive bonuses?
	5.3.4 Traitements - AMM (FDA, EMA,...)
Cabozantinib Approval Expands Initial Treatment Options for Advanced Kidney Cancer [NCI] “There are a lot of trials of drug combinations that are beginning to report results,” Dr. Rini said. “We expect this whole landscape is going to change in the next year or so. We won’t be giving single TKIs to patients with metastatic RCC as front-line therapy for very long.”
	5.4 Traitements - Economie
U.S. Prescription Drug Costs Are a Crime [Bloomberg] The U.S. should also do what so many other countries do: negotiate.
	6. Lutte contre les cancers
Patients and researchers team up to fight metastatic prostate cancer [Broad Institute] Internet-driven, direct-to-patient engagement allows men to volunteer medical data, speed research.
More People Living With HIV and Cancer Should Get Appropriate Cancer Treatment, According to New Guidelines [NCCN] The new NCCN Guidelines for Cancer in People Living With HIV includes general advice — while highlighting the importance of working in collaboration with an HIV specialist — as well as specific treatment recommendations for non-small cell lung cancer (NSCLC), anal cancer, Hodgkin lymphoma, and cervical cancer.
Why rare cancers deserve a greater focus and a more targeted approach [Institute of Cancer Research] Professor Winette van der Graaf, Professor of Personalised Oncology at The Institute of Cancer Research, London, shares her experiences of research into rare cancers and how to improve outcomes for patients.
Broad, Dana-Farber Launch Patient-Driven Prostate Cancer Project [Genome Web] Called the Metastatic Prostate Cancer (MPC) Project, the program allows prostate cancer patients to fill out a demographic and medical history survey on its website. Patients will then be sent a saliva-collection kit — and in some cases a blood biopsy kit, as well — to provide MPC researchers with samples for DNA sequencing.
Basic Research: Building a Firm Foundation for Biomedicine [NIH Director's Blog] All in all, the findings show that the contribution of publicly supported basic science to the development of the most promising recent new therapeutic advances has been even greater than had been appreciated.
	6.10 Politiques
Merkel makes a surprise pick for German research minister [Science] Trained as a banker, she worked as a hotel manager before being elected to the German Parliament in 2013. There, she worked mostly on finance issues. Unlike her three predecessors, all women, Karliczek has had little contact with research or education policy and has no Ph.D.
	6.10.1 Politiques (USA)
On Drug Pricing, States Step In Where Washington Fails [NY Times] Most advocates concede that comprehensive reform of the American drug pricing system will have to come from national-level changes. Some think the flurry of state legislation will kick-start the federal process.
	6.11 Patients
I have brain cancer. Drug companies and med schools should be compensating me for my expertise [STAT] Don’t get me wrong. I’m not suggesting that volunteer work be eliminated in favor of compensated work. But medical education and industry should recognize patient contributions through fair compensation, commensurate with the work performed. If a patient delivers a service that a professional might otherwise provide, the patient is entitled to similar compensation.
	6.12 Ethique
A code of ethics to get scientists talking [Nature] A set of guidelines could trigger positive action.
	6.6 Publications
Cancer researcher under cloud of suspicion wins $300,000 science prize [Retraction Watch] The committee that recommended Croce for the Dan David Prize was chaired by one of Croce’s long-time collaborators Peter Vogt, who runs a lab at The Scripps Research Institute in La Jolla, California. Croce has also co-authored several papers with two other members of the committee—Webster K. Cavenee and Nancy Jenkins.
Transparency in authors’ contributions and responsibilities to promote integrity in scientific publication [PNAS] We recommend that journals adopt common and transparent standards for authorship, outline responsibilities for corresponding authors, adopt the Contributor Roles Taxonomy (CRediT) methodology for attributing contributions, include this information in article metadata, and require authors to use the ORCID persistent digital identifier.